Plant Medicine for Addiction & Mental Health, What the Research Actually Says.

Twenty years ago, suggesting that psilocybin or MDMA could treat depression, addiction, or PTSD was a fringe position. In 2026 it is the central conversation happening at the FDA, at the National Institutes of Mental Health, and inside the world’s leading academic psychiatry departments. The research has caught up to what indigenous traditions and a handful of pioneering clinicians knew for decades. The work is real, the evidence base is strong, and the questions families ask, is it safe, does it work, who is it for, deserve answers anchored to actual science, not marketing copy.

This is the honest version, current as of June 2026, written by someone who has been inside the behavioral health system for over 11 years and walks clients through preparation and integration every week.

Where does ketamine fit, and what exactly is FDA approved?

Ketamine is the only compound in this conversation that is legally available in the United States today, as a Schedule III anesthetic that clinicians prescribe off label for depression. The only FDA approved psychiatric product in this space is esketamine nasal spray, sold as Spravato, and its approval is narrower than most people assume.

The approval history is specific, and worth knowing before anyone signs up for anything:

• 2019. Esketamine approved for treatment resistant depression in adults, to be used together with an oral antidepressant.
• 2020. Approved for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior, again alongside an oral antidepressant.
• January 2025. Approved as the first monotherapy for treatment resistant depression, meaning it can now be used without a companion antidepressant.

Three things follow from that list. First, esketamine is not approved for any substance use disorder. Not alcohol, not opioids, not stimulants. Any clinic marketing it that way is describing off label use. Second, esketamine is dispensed under a restricted safety program and administered in a certified healthcare setting with monitoring after each dose, because of sedation, dissociation, and abuse potential. Third, the intravenous racemic ketamine offered at infusion clinics is a different thing entirely. It is legal, it is off label, and it has never been reviewed by FDA for depression, which means protocols, screening rigor, and follow up vary enormously between providers.

For a recovery population there is one more consideration that rarely makes the marketing. Ketamine has real abuse liability and ketamine use disorder is documented in the clinical literature. For someone with an active or recent substance use disorder, at home ketamine, take home lozenges, or loosely monitored infusion series deserve a hard look and a prescribing physician who knows the full history.

Epic Journey is not a medical provider. We do not prescribe, administer, or arrange any of these treatments. What we do is coordination, honest screening conversations, and the preparation and integration work around whatever a licensed clinician decides. If you want an unbiased read on your situation, that is what the free consult is for.

How strong is the psilocybin evidence, and where does it stop?

Psilocybin for depression is the strongest evidence in this field and has now cleared Phase 3, with Compass Pathways reporting that COMP360 met its primary endpoint in both of its Phase 3 trials. The addiction evidence is a full step behind that: the alcohol and tobacco studies are Phase 2 and pilot trials with fewer than 100 participants each, and no psilocybin product is approved for any substance use disorder anywhere.

What the depression data actually shows: the Phase 2 trial in the New England Journal of Medicine found a single 25mg dose reduced depression scores at three weeks in treatment resistant depression, and Compass has since reported positive Phase 3 results. That is a real regulatory path. It is also a path that has not finished, and an FDA submission is not an approval.

What the addiction data actually shows:

• Alcohol use disorder. The Bogenschutz trial in JAMA Psychiatry randomized 95 adults and reported 9.7 percent heavy drinking days in the psilocybin group versus 23.6 percent with active placebo across weeks 5 to 36. Strong signal, one site, Phase 2, no Phase 3 result yet.
• Tobacco. The often quoted 80 percent abstinence figure came from a 15 person open label pilot and should no longer be cited as the current number. The randomized follow up, published in JAMA Network Open in March 2026, enrolled 82 smokers and found 40.5 percent verified abstinence at six months with psilocybin versus 10.0 percent with a nicotine patch. Still a large effect. Roughly half the headline number, and the trial was unblinded.
• Opioid use disorder. There is no meaningful psilocybin evidence base here at all.

On safety, psilocybin does not appear to carry ibogaine's cardiac liability. Research in the International Journal of Neuropsychopharmacology found that psilocybin's charged phosphate group impedes membrane diffusion and keeps it from reaching the hERG binding site, and that its active metabolite psilocin does not meaningfully inhibit hERG at clinical concentrations. Psilocybin still raises blood pressure and heart rate transiently, and the psychiatric exclusions in this article still apply.

Why is ibogaine the one compound here with a documented pattern of deaths?

Ibogaine and its long lived metabolite noribogaine block the hERG potassium channel in heart muscle, which prolongs the QT interval and can trigger torsades de pointes, ventricular fibrillation, and cardiac arrest. That risk is not theoretical, and it is not evenly distributed: the deaths recorded in the published literature cluster almost entirely among people who took ibogaine to get off opioids, which is exactly the population that goes looking for it.

The mechanism is well characterized. Laboratory work published in the Journal of Biological Chemistry and summarized in PubMed showed ibogaine inhibits hERG currents at low micromolar concentrations. The New England Journal of Medicine published a case report of long QT syndrome induced by ibogaine in a 31 year old woman whose QT interval reached 548 milliseconds after a single dose. A 2026 scoping review in Molecules, indexed at PubMed Central, catalogs cases with QTc intervals above 600 milliseconds, torsades de pointes, and cardiac arrest requiring defibrillation.

The numbers that should stop anyone considering this for an opioid detox:

• A 2026 multisite analysis of 19,071 ibogaine treatments across international clinics, posted as a preprint on Research Square, found six deaths within 72 hours of treatment. All six were people treated for opioid use disorder. None occurred among the 8,689 patients treated for non substance use indications.
• The same paper's updated systematic review of fatalities found that 41 of 44 deaths with a known indication involved substance use disorders, predominantly opioid detoxification.
• Earlier forensic work by Alper and colleagues, published in the Journal of Forensic Sciences, documented deaths temporally associated with ibogaine ingestion.

Why does the risk concentrate there? Opioid withdrawal involves vomiting, diarrhea, and fluid loss, and the resulting electrolyte abnormalities are established risk factors for drug induced long QT. Methadone independently prolongs QT. Layer a potent hERG blocker on top of that, in a clinic with uncertain monitoring, and you have the setup the fatality data describes. A normal screening ECG is necessary and not sufficient. Severe QT prolongation has been documented at therapeutic doses in people with no known heart disease.

What is the actual legal status of these compounds in the United States right now?

Every compound discussed in this article except ketamine is a Schedule I controlled substance under federal law, and none of them is FDA approved for addiction or for any other indication. Ketamine is the only one legally available in the United States, as a Schedule III anesthetic prescribed off label, with one approved psychiatric product in the esketamine nasal spray sold as Spravato.

The detail underneath that headline matters, because the differences are large:

• Psilocybin. Schedule I federally. Two states run their own regulated frameworks: Oregon licenses service centers through Oregon Psilocybin Services under Measure 109, now codified as ORS 475A, and Colorado licenses healing centers through the state Natural Medicine Division, which issued its first license in March 2025. These are state supervised service models, not medical prescriptions, and they do not change federal status.
• Ibogaine. Schedule I, not approved anywhere in the United States, and not available through any legal domestic pathway. Nearly all ibogaine treatment happens at clinics in other countries, where oversight ranges from genuine hospital grade cardiac monitoring down to essentially none. There is no FDA equivalent certifying those clinics and no public registry a family can check.
• Ayahuasca and DMT. DMT is Schedule I. A narrow religious exemption exists for specific churches under federal religious freedom case law. Retreats abroad are not covered by it.
• MDMA. Schedule I and not approved. The FDA declined the application in August 2024.

Two funding developments get misread as approvals. Texas appropriated 50 million dollars in June 2025 for FDA aligned ibogaine trials, and after no drug company met the state matching terms, the award went to UTHealth Houston and UTMB. Separately, Executive Order 14401, signed April 18, 2026, directs at least 50 million federal dollars toward state psychedelic programs and instructs FDA and DEA to build a Right to Try pathway. Money for trials is not evidence of safety and it is not approval. Nothing in that order makes ibogaine legal or available today.

What plant medicine actually means

The phrase “plant medicine” gets used loosely. In a clinical and recovery context, it refers to a specific set of compounds, some plant-derived, some synthesized to chemically identical forms, used in carefully structured settings for specific therapeutic goals. The main ones being studied or used clinically in 2026:

• Psilocybin, the active compound in psychedelic mushrooms. The most-studied compound in the modern psychedelic renaissance.
• Ayahuasca, an Amazonian brew combining DMT and an MAOI, used ceremonially for centuries and now studied in academic settings.
• Ibogaine, from the West African Tabernanthe iboga plant, used primarily for opioid use disorder in licensed medical clinics outside the U.S.
• MDMA, technically synthesized, not plant-derived, but typically grouped here. Used in clinical trials for PTSD.
• 5-MeO-DMT (Bufo), a brief, profound non-dual compound, originally from a Sonoran Desert toad, increasingly studied in synthetic form.
• Ketamine, not a classical psychedelic, and frequently misdescribed. Generic ketamine is a Schedule III anesthetic that is legal nationally and used off label for depression, with no FDA approval for that use. The approved product is esketamine nasal spray (Spravato), cleared in 2019 for treatment resistant depression alongside an oral antidepressant and in January 2025 as a monotherapy. Neither is approved for any substance use disorder and has reshaped what mainstream psychiatry believes is possible.

For a deeper service-level breakdown of how we work with each of these, see our dedicated plant medicine integration page.

Where the research actually comes from

The center of gravity for modern psychedelic research is concentrated in a handful of institutions. If you’re going to trust any sources, trust these:

• Johns Hopkins Center for Psychedelic & Consciousness Research, the leading U.S. academic center, running trials in depression, addiction, end-of-life anxiety, and more.
• Imperial College London Centre for Psychedelic Research, led by Robin Carhart-Harris, foundational neuroimaging work on the default mode network.
• NYU Langone Center for Psychedelic Medicine, alcohol use disorder, end-of-life cancer anxiety.
• MAPS (Multidisciplinary Association for Psychedelic Studies), the non-profit research organization that sponsored the MDMA-for-PTSD Phase 3 trials.
• COMPASS Pathways, pharmaceutical sponsor of the synthetic psilocybin trials for treatment-resistant depression.
• The FDA, granted psilocybin Breakthrough Therapy designation in 2018 (treatment-resistant depression) and 2019 (major depressive disorder).

For addiction, what the data shows

Three substance use disorders have meaningful published evidence as of 2026. None of this is a cure. All of it is the strongest signal mainstream addiction medicine has seen in decades for the populations these compounds were studied in.

Alcohol use disorder

The landmark trial from Michael Bogenschutz at NYU, published in JAMA Psychiatry in 2022, randomized adults with alcohol use disorder to either psilocybin-assisted therapy or placebo-assisted therapy. The psilocybin group showed a substantial reduction in heavy drinking days at 8-month follow-up, with effect sizes that have not been seen with conventional pharmacotherapy.

Tobacco / nicotine use disorder

Matthew Johnson and colleagues at Johns Hopkins ran an open-label pilot study of psilocybin-assisted smoking cessation. The randomized follow up trial, published in JAMA Network Open in March 2026, enrolled 82 smokers and found 40.5 percent biologically verified abstinence at 6 months in the psilocybin group versus 10.0 percent with a nicotine patch. That is a large effect and it is roughly half the 80 percent figure widely quoted from the earlier 15 person open label pilot. The trial was unblinded and the sample was not demographically diverse Hopkins research summary.

Opioid use disorder

This is where ibogaine sits. Multiple observational studies from licensed medical clinics in Mexico and New Zealand have documented significant reductions in opioid withdrawal severity and post-treatment opioid craving after a single ibogaine treatment. NCBI/NIH summary of the observational evidence base. Ibogaine is also the one compound in this article with a documented pattern of deaths, and those deaths concentrate specifically in opioid detoxification. A 2026 multisite analysis of 19,071 treatments found six deaths within 72 hours, every one of them in a patient treated for opioid use disorder, and none among the 8,689 patients treated for non substance use indications. The mechanism is hERG potassium channel blockade causing QT prolongation and potentially fatal arrhythmias. Ibogaine is not approved in the United States and the clinics abroad that provide it are not licensed by any FDA equivalent. Read the cardiac risk section below before you consider this for anyone.

For mental health, what the data shows

Major depressive disorder & treatment-resistant depression

This is the most-studied indication in the entire field. Two landmark trials anchor the evidence:

• Davis et al. at Johns Hopkins, published in JAMA Psychiatry, 2021. Two doses of psilocybin combined with supportive psychotherapy produced rapid, large, and sustained antidepressant effects in adults with major depressive disorder. Effects persisted at 12-month follow-up.
• COMPASS Pathways Phase 2 trial for treatment-resistant depression, published in The New England Journal of Medicine, 2022. A single 25mg dose of synthetic psilocybin produced significant reductions in depression scores at 3 weeks.

The FDA granted psilocybin Breakthrough Therapy designation in 2018 for treatment-resistant depression and again in 2019 for major depressive disorder, reserved for therapies showing substantial improvement over existing treatments for serious conditions.

PTSD

MDMA-assisted therapy completed Phase 3 trials sponsored by MAPS in 2021-2022, with two studies published in Nature Medicine. The trials showed large reductions in PTSD symptoms, including in clients with prior treatment failures.

Important update: In August 2024, the FDA declined to approve MDMA-assisted therapy in its first review, citing concerns about trial design and the difficulty of blinding. The Complete Response Letter, made public in September 2025, asked Lykos to run an additional Phase 3 trial before FDA would reconsider. Lykos has said it intends to do so and has restructured heavily in the meantime. There is no resubmission pending. A new Phase 3 trial plus review realistically puts any approval decision years out. MDMA remains federally Schedule I in the U.S. and is not currently available outside of compassionate-use or international clinical settings.

End-of-life anxiety & existential distress

The earliest modern psilocybin trials targeted patients with life-threatening cancer and accompanying existential distress. Roland Griffiths at Johns Hopkins and Stephen Ross at NYU independently demonstrated that single-dose psilocybin produced significant, durable reductions in depression and end-of-life anxiety in this population, with effects persisting at 6-month follow-up. Hopkins summary.

The questions people actually ask

Is it safe?

In properly screened candidates, in legally licensed settings, with trained facilitators and integration support, the safety profile is strong. The Hopkins, NYU, and Imperial trials report low rates of serious adverse events. Where harm clusters: in underground or unscreened use, in people with personal or first-degree-relative history of schizophrenia or bipolar I (who can be precipitated into psychotic episodes), in untreated cardiac conditions for ibogaine and ayahuasca, and when integration is absent afterward.

The screening process is what makes the experience safe. We have turned clients away and we will continue to.

Is it legal?

Most classical psychedelics remain federally Schedule I in the United States. But state-level frameworks exist:

• Oregon (Measure 109), licensed psilocybin service centers, operational since 2023.
• Colorado (Proposition 122), Natural Medicine Health Act. The first healing center license was issued in March 2025 and the first regulated session took place in June 2025. The program is operating, with both full healing center and micro healing center license types.
• Ketamine, legal nationally, used off-label for depression in clinical settings.
• International clinics, Mexico (ibogaine), Costa Rica and Peru (ayahuasca), the Netherlands (psilocybin truffles), and Jamaica (psilocybin) all have legal or decriminalized frameworks where licensed work happens.

Epic Journey does not administer plant medicine in California. We provide preparation and integration, and refer to vetted, legally licensed partner facilities in the jurisdictions above for the ceremony itself. We do not refer to underground or unlicensed work.

What does it feel like?

For psilocybin: most clinical-protocol sessions run 4-6 hours from onset. Participants typically lie down with eye shades and curated music, accompanied by one or two trained facilitators. Experiences vary widely but commonly include emotional release, vivid imagery, expanded awareness, somatic sensations, and what researchers describe as “mystical-type” experiences. Difficult passages are common and considered therapeutically meaningful when held in a safe container.

For ayahuasca, sessions run 4-6 hours, are typically ceremonial in nature, and frequently involve physical purging which is considered part of the work. For ibogaine, sessions are far longer (20-30 hours) and more physiologically intense, which is why they happen only in licensed medical settings.

Who shouldn’t do it?

The honest list:

• Personal or first-degree-relative history of schizophrenia, bipolar I, or psychotic disorders.
• Active suicidality or recent psychiatric hospitalization.
• Any cardiac condition, and for ibogaine specifically, any QT prolonging medication, any electrolyte disturbance, and any active opioid withdrawal. A clean cardiac history does not clear someone for ibogaine. Severe QT prolongation and fatal arrhythmias have been documented at therapeutic doses in people with no known heart disease.
• Pregnancy or breastfeeding.
• Current SSRI, MAOI, or lithium use without medically supervised taper.
• Active substance use disorder without prior stabilization (typically 90 days).
• Unrealistic expectations, anyone expecting the medicine to “fix” them without doing the work before and after.

Why is integration so important?

Every legitimate research protocol, Johns Hopkins, NYU, Imperial, MAPS, COMPASS, treats post-session psychotherapy as non-negotiable. Research consistently identifies integration support as the strongest predictor of whether peak experiences produce durable behavioral change.

The medicine opens the door. Integration is whether you walk through any of them.

Without integration, insights fade within weeks. With it, they restructure how a person actually lives. We recommend a minimum of 60 days of weekly post-ceremony integration with someone who knows exactly what was encountered.

How much does it cost?

Cash-pay only. Neither preparation, nor the ceremony itself, nor integration are insurance-reimbursable for plant medicine work. Real ranges as of 2026:

• Oregon psilocybin service centers: typically $3,000-$6,000 per session.
• International ayahuasca and psilocybin retreats: $5,000-$15,000 depending on facility, duration, and accommodations.
• Ibogaine programs in licensed Mexican medical clinics: $8,000-$20,000+ given the medical oversight requirements.
• Epic Journey preparation and integration packages: quoted on the consult based on the protocol your situation needs.

What plant medicine research actually means for you

If you or someone you love is considering this work, here’s the honest version:

1. The evidence base is real. This is not New Age marketing. It’s peer-reviewed research from the world’s leading psychiatry institutions.
2. The medicine is not the work. The medicine is the catalyst. The work is what happens in the months before and after.
3. This work is not for everyone. Honest clinical screening matters more than enthusiasm.
4. Underground and unlicensed work is where most of the harm in this space happens. Don’t do it.
5. Integration is non-negotiable. If you don’t have someone walking you through the 60 days after, the experience will fade.

For the full Epic Journey approach to plant medicine, how we prepare clients, who we work with, the partner facilities we trust, and the integration model we run, see /plant-medicine.html. For the full 3-phase protocol this work sits inside, see The Epic Method™.

If you’re trying to figure out whether this work might be right for you or your loved one, that’s exactly the conversation the free 15-minute consult is built for. Honest read, no sales pitch.